open access

Vol 5, No 3 (2009)
Review paper
Published online: 2009-05-15
Get Citation

Management of oncology patients with history of cardiovascular diseases

Kalina Kawecka-Jaszcz, Agnieszka Bednarek, Katarzyna Styczkiewicz
Onkol. Prak. Klin 2009;5(3):83-91.

open access

Vol 5, No 3 (2009)
REVIEW ARTICLES
Published online: 2009-05-15

Abstract

Cardiovascular diseases (CVDs) and cancers are the main causes of death, therefore oncological patient often suffers from cardiologic disease. Intensive chemotherapy improves the prognosis, reduces mortality and lengthens life of oncological patients but it is also connected with applying of potentially cardiotoxic drugs. In this article, we presented the risk factors of CVDs and the methods of its individual estimation in order to perform qualification and treatment monitoring in subjects at baseline increased risk of cardiac disease. We described treatment of myocardial ischemia, hypertension and congestive heart failure in this patients. On example of anthracyclines and trastuzumab the mechanisms of the cardiotoxicity of drugs used in oncology, monitoring of potentially cardiotoxic treatment and strategies to reduce cardiovascular toxicity were presented.

Abstract

Cardiovascular diseases (CVDs) and cancers are the main causes of death, therefore oncological patient often suffers from cardiologic disease. Intensive chemotherapy improves the prognosis, reduces mortality and lengthens life of oncological patients but it is also connected with applying of potentially cardiotoxic drugs. In this article, we presented the risk factors of CVDs and the methods of its individual estimation in order to perform qualification and treatment monitoring in subjects at baseline increased risk of cardiac disease. We described treatment of myocardial ischemia, hypertension and congestive heart failure in this patients. On example of anthracyclines and trastuzumab the mechanisms of the cardiotoxicity of drugs used in oncology, monitoring of potentially cardiotoxic treatment and strategies to reduce cardiovascular toxicity were presented.
Get Citation

Keywords

cardiovascular diseases; cancer; chemotherapy; risk factors; cardiotoxicity

About this article
Title

Management of oncology patients with history of cardiovascular diseases

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 3 (2009)

Article type

Review paper

Pages

83-91

Published online

2009-05-15

Bibliographic record

Onkol. Prak. Klin 2009;5(3):83-91.

Keywords

cardiovascular diseases
cancer
chemotherapy
risk factors
cardiotoxicity

Authors

Kalina Kawecka-Jaszcz
Agnieszka Bednarek
Katarzyna Styczkiewicz

References (51)
  1. Główny Urząd Statystyczny. Mały rocznik statystyczny Polski 2008.
  2. Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8(9): 784–796.
  3. Yeh ETH, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109(25): 3122–3131.
  4. Schultz PN, Beck ML, Stava C, et al. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003; 104(4): 488–495.
  5. Khakoo AY, Yeh ETH. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008; 5(11): 655–667.
  6. World Health Organization (WHO). 2007. Health for All database (HFA-DB). Copenhagen: WHO Regional Office for Europe. Http://www.euro.who.int/hfadb.
  7. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937–952.
  8. Barnoya J, Bialous SA, Glantz SA. Effective interventions to reduce smoking-induced heart disease around the world: time to act. Circulation. 2005; 112(4): 456–458.
  9. Raupach T, Schäfer K, Konstantinides S, et al. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J. 2006; 27(4): 386–392.
  10. Tonstad S, Andrew Johnston J. Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil. 2006; 13(4): 507–514.
  11. Kawecka-Jaszcz K, Jankowski P, Podolec P, et al. ish forum for prevention guidelines on smoking. Kardiol Pol. 2008; 66: 125–126.
  12. Pająk A, Jankowski P, Kawecka-Jaszcz K, et al. Zmiany we wtórnej prewencji choroby niedokrwiennej serca po wypisie ze szpitala w okresie dekady lat 1997-2007. Wyniki Krakowskiego Programu Wtórnej Prewencji Choroby Niedokrwiennej Serca oraz polskiej części badań EUROASPIRE II i EUROASPIRE III. Kardiol Pol. 2009.
  13. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007; 28(12): 1462–1536.
  14. Braithwaite D, Tammemagi CM, Moore DH, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009; 124(5): 1213–1219.
  15. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 2007; 28: 2375–2414.
  16. MacDonald JS, Gerson RJ, Kornbrust DJ, et al. Preclinical evaluation of lovastatin. Am J Cardiol. 1988; 62(15): 16J–27J.
  17. Smith PF, Grossman SJ, Gerson RJ, et al. Studies on the mechanism of simvastatin-induced thyroid hypertrophy and follicular cell adenoma in the rat. Toxicol Pathol. 1991; 19(3): 197–205.
  18. Narisawa T, Fukaura Y, Tanida N, et al. Chemopreventive efficacy of low dose of pravastatin, an HMGCoA reductase inhibitor, on 1, 2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med. 1996; 180: 131–138.
  19. Narisawa T, Morotomi M, Fukaura Y, et al. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res. 1996; 87(8): 798–804.
  20. Mrówka P, Głodkowska E. Statyny w prewencji i terapii chorób nowotworowych. Onkol Prak Klin. 2008; 5: 171–191.
  21. Zdrojewski T, Babińska Z, Bandosz P, et al. Związek nadwagi i otyłości podwyższonymi wartościami ciśnienia tętniczego w badaniach reprezentatywnych grup dorosłych Polaków w 1997 i 2002 roku. (NATPOL II, NATPOL III). Med Metabol. 2002; 4: 32–37.
  22. Kłosiewicz-Latoszek L, Szostak W, Podolec P, et al. Konsensus Rady Redakcyjnej PFP dotyczący zasad prawidłowego żywienia. Forum Profilaktyki. 2008; 1: 1–3.
  23. Stolarz-Skrzypek K, Kawecka-Jaszcz K. Ograniczenie spożycia soli kuchennej jako metoda prewencji nadciśnienia tętniczego. Postępy Nauk Medycznych. 2009; 1: 34–38.
  24. Salt as a Vehicle for Fortification. Report of a WHO Expert Consultation. Luxemburg, 21-22.03.2007.
  25. Bello N, Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis. 2004; 46(4): 287–295.
  26. Mosca L, Ferris A, Fabunmi R, et al. Tracking Women`s Avareness of Heart Disease. Circulation. 2004; 109: 573–579.
  27. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113(6): 791–798.
  28. Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007; 50(15): 1435–1441.
  29. Fox K, Garcia MA, Ardissino D, et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology, ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27(11): 1341–1381.
  30. Collet JP, Roffi M, Mueller C, et al. Authors:, Authors, Authors, Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology, ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008; 29(23): 2909–2945.
  31. Yusuf SW, Razeghi P, Yeh ETH. The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol. 2008; 33(4): 163–196.
  32. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the ure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail. 2008; 10: 933–989.
  33. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342(15): 1077–1084.
  34. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005; 23(13): 2900–2902.
  35. Deptała A, Omyła-Staszewska J, Staszewska-Skurczyńska M. Kardiotoksyczność antracyklin i kardioprotekcja. Fakty i mity. . Współcz. Onkol. 2004; 8(2): 107–111.
  36. Szmit S, Grabowski M. Niewydolność serca jako powikłanie leczenia onkologicznego - nowe wyzwanie. Kardiologia na co Dzień. 2008; 3: 95–98.
  37. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003; 97(11): 2869–2879.
  38. Łacko A, Matkowski R, Gisterek I, et al. Moleculary targeted therapy side effects. Adv Clin Exp Med. 2006; 15: 723–731.
  39. Martín M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist. 2009; 14(1): 1–11.
  40. Piccart-Gebhart M, Procter M, Leyland-ones B, et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Eng J Med. 2005; 109: 3122–3131.
  41. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. Herceptin Adjuvant (HERA) Trial Study Team, HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007; 369(9555): 29–36.
  42. Yeh ETH, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109(25): 3122–3131.
  43. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines. Cancer. 2004; 100(10): 2052–2063.
  44. Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol. 2008; 15(Suppl 1): S16–S29.
  45. Sengupta PP, Northfelt DW, Gentile F, et al. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc. 2008; 83(2): 197–203.
  46. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002; 20(5): 1215–1221.
  47. Rastogi P. American Society of Clinical Oncology 43rd Annual Meeting; June 4, 2007; Chicago, IL. Late-breaking abstract 513. Chicago, 04.05.2007.
  48. Barrett-Lee PJ, Dixon JM, Farrell C, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol. 2009; 20(5): 816–827.
  49. Galderisi M, Marra F, Esposito R, et al. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound. 2007; 5: 4.
  50. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009; 10(4): 391–399.
  51. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006; 114(23): 2474–2481.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl